Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share 
Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture 
$16B Michigan Data Center Project Boosts U.S. AI Infrastructure Expansion 
Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
Meta Expands AI Training With Employee Activity Tracking Tools 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
Kakaku.com Stock Surges on EQT Takeover Interest Amid Rising Japan Deal Activity 
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
BURLINGTON, Mass., March 28, 2017 -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that Michael Clayman, M.D., President and Chief Executive Officer, will present at Needham & Company’s 16th Annual Healthcare Conference on Tuesday, April 4, 2017 at 3:40 p.m. EDT at the Westin Grand Central Hotel in New York.
To access the live webcast and subsequent archived recordings for the presentation, please visit the Flexion website at http://flexiontherapeutics.com/.
About Flexion Therapeutics
Flexion is a specialty pharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA). The company's lead product candidate, Zilretta™ (FX006), is being investigated for its potential to provide improved analgesia for the millions of U.S. patients who receive intra-articular injections for OA related knee pain annually.
Corporate Contact: Scott Young Sr. Director, Corporate Communications & Investor Relations Flexion Therapeutics, Inc. T: 781-305-7194 [email protected]
